newsfilter
← Latest News
Business Wire·

Enanta Pharmaceuticals Reports Financial Results for its Fiscal First Quarter Ended December 31, 2025

Conducting Phase 3 Enabling Activities, Including Discussions with U.S. Food & Drug Administration (FDA), for Zelicapavir, an N-Protein Inhibitor in Development to Treat Respiratory Syncytial Virus